SecurityDRYS / DryShips, Inc. (Y2109Q101)
Institutional Owners21
Institutional Shares75,988,994
Institutional Value$ 13,055,000 USD

Institutional Stock Ownership and Shareholders

DRYS / DryShips, Inc. Institutional Ownership

DryShips, Inc. (NASDAQ:DRYS) has 21 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 75,988,994 shares. Largest shareholders include Economou George, Marshall Wace LLP, Apollo Management Holdings, L.P., Oceanic Investment Management LTD, Susquehanna Fundamental Investments, Llc, Morgan Stanley, Virtu Financial LLC, Creative Planning, Millennium Management Llc, and Deutsche Bank Ag\.
DryShips, Inc. (NASDAQ:DRYS) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/drys"><img src="https://images.fintel.io/us-drys-so.png" alt="DRYS / DryShips, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR BARCLAYS PLC 82 16,600 20,143.90 0 61
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 6,338 2,595 -59.06 22 9 -59.09
2018-05-14 13F-HR Pacad Investment Ltd. 100 0 -100.00 0 0
2018-01-19 13F-HR Winslow, Evans & Crocker, Inc. 16 0 -100.00 38 0 -100.00
2018-05-15 13F-HR Oceanic Investment Management LTD 473,405 411,505 -13.08 1,671 1,506 -9.87
2018-05-15 13F-HR Apollo Management Holdings, L.P. 0 963,700 0 3,527
2018-02-08 13F-HR SEI INVESTMENTS CO 81,300 0 -100.00 200 0 -100.00
2018-05-10 13F-HR JP Morgan Chase & Co 8,944 0 -100.00 32 0 -100.00
2018-05-15 13F-HR Marshall Wace LLP 1,560,925 1,328,203 -14.91 5,510 4,861 -11.78
2018-05-15 13F-HR Ionic Capital Management LLC 251,117 0 -100.00 887 0 -100.00
2018-05-15 13F-HR JANE STREET GROUP, LLC 12,883 0 -100.00 45 0 -100.00
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 220,066 62,314 -71.68 777 228 -70.66
2018-05-15 13F-HR BlueCrest Capital Management Ltd 0 25,801 0 94
2018-05-14 13F-HR Virtu Financial LLC 66,509 243
2018-05-15 13F-HR SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC 267,275 978
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 3 3 0.00 0 0
2018-02-14 13F-HR ROYAL BANK OF CANADA 1,000 0 -100.00 2 0 -100.00
2018-01-16 13F-HR NEXT Financial Group, Inc 4,200 0 -100.00 13 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 71 10 -85.92 0 0
2018-02-16 13F-HR/A Commonwealth Equity Services, Inc 10,619 0 -100.00 18 0 -100.00
2018-05-15 13F-HR UBS Group AG 7 3,777 53,857.14 0 14
2018-04-18 13F-HR Creative Planning 72,478 64,978 -10.35 256 238 -7.03
2018-05-15 13F-HR Jefferies Group LLC 443,687 50,000 -88.73 1,566 183 -88.31
2018-04-16 13F-HR WESPAC Advisors SoCal, LLC 100 100 0.00 0 0
2018-01-16 13F-HR BANK OF MONTREAL /CAN/ 40 0 -100.00 0 0
2018-05-15 13F-HR Squarepoint Ops LLC 45,062 0 -100.00 159 0 -100.00
2018-05-11 13F-HR Covalis Capital Llp 38,445 0 -100.00 136 0 -100.00
2018-05-16 SC 13D/A Economou George 72,421,515 72,421,515 0.00
2018-05-09 13F-HR IFP Advisors, Inc 2 2 0.00 0 0
2018-05-14 13F-HR Quinn Opportunity Partners LLC 16,000 0 -100.00 56 0 -100.00
2018-05-02 13F-HR Creative Financial Designs Inc /adv 6 0 -100.00 0 0
2018-02-09 13F-HR PNC FINANCIAL SERVICES GROUP, INC. 20 0 -100.00 0 0
2018-05-15 13F-HR TWO SIGMA SECURITIES, LLC 0 15,188 0 56
2018-05-15 13F-HR DEUTSCHE BANK AG\ 75,424 58,024 -23.07 266 212 -20.30
2018-05-14 13F-HR Centenus Global Management, Lp 78,000 0 -100.00 275 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 6,736 230,595 3,323.32 24 844 3,416.67
2018-05-10 13F-HR Wagner Wealth Management, Llc 550 300 -45.45 2 1 -50.00
DRYS : DryShips Stock Analysis and Research Report

2017-10-19 - Asif

DryShips Inc., a corporation organized under the laws of the Republic of the Marshall Islands, was formed on September 9, 2004. its principal executive offices are located at 109 Kifisias Avenue and Sina Street, Marousi, GR 151 24 Greece. Business Development Developments related to Ocean Rig On October 29, 2014, DryShips completed the issuance of 20,833 of its common shares (250,000,000 common shares before the reverse stock splits) in a public offering amounting to net proceeds to it of $332.9 million. On June 8, 2015, Ocean Rig, successfully completed the offering of 28,571,428 shares of its common stock, par value $0.01 per share, at a price of $7.00 per share, resulting in proceeds of $194.1 million, after deducting placement fees. As a result of the offering DryShips lost itscontrolling financial interest in Ocean Rig, therefore, from June 8, 2015, Ocean Rig has been considered as an affiliated entity and not as a controlled subsidiary. On June 4, 2015, Dry...

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Diana Containerships - Great Value But Kalani-Related Dilution Still Ongoing

2018-05-23 seekingalpha
Latest sale will leave the company debt-free with the remaining four-vessel fleet being worth an estimated $60 million. (81-3)

TOP Ships: More Acquisitions? Get Ready For More Dilution

2018-02-26 seekingalpha
TOP Ships announces acquisition of two new build Suezmaxes and one MR in its year end earnings release. (81-25)

UPDATE 1-Hedge funds hook shipping stocks grappling for recovery

2018-02-15 reuters
LONDON (Reuters) - Shipping stocks may still be in the doldrums in the view of many investors, but hedge funds have bet at least $675 million on signs of renewed buoyancy in the industry. (52-1)

Investing In DryShips Is A Dangerous Game At Best

2018-02-12 seekingalpha
Share prices jumped almost 25% on Monday due to a dividend announcement and authorized stock buyback. This is a short-term jump - not the start of turnaround. (37-0)

CUSIP: Y2109Q101